• Earlier this month, FoundationOne CDx was approved to identify mutations that lead to MET exon 14 skipping in advanced non-small cell lung cancer (NSCLC) and match patients with a new targeted therapy, which was approved in parallel. This simultaneous approval presents a new treatment option for the 2-3% of lung …

    Continue Reading

  • Recognizing Value Through Collaboration

    As adoption of comprehensive genomic profiling (CGP) becomes more widespread in cancer treatment, new research is redefining the clinical utility of diagnostic tests in this age of precision medicine. The value of CGP lies in helping to inform decisions on available treatment options, including clinical trial …

    Continue Reading

  • Personalized: Lung cancer’s present offers a glimpse at cancer’s future

    The impact of precision medicine on cancer treatment becomes more apparent each day. If you consider the patient experience, you start to see how much has changed already — and how much more is possible. When I began caring for patients with non-small cell lung cancer (NSCLC) about 30 years ago, the major therapeutic …

    Continue Reading